Sino’s Chief Business Officer shared the story of the company’s work in recombinant proteins, antibodies and CRO services on the network on 1 February 2026
Chief Business Officer Dr. Rob Burgess told the story of Sino Biological’s contribution to Global Biomedical Research in an exclusive segment on Fox Business Network which aired on February 1, 2026 at 4:30pm EST.
Biotechnology company and deliverer of recombinant proteins, antibodies, and CRO services, Sino Biological featured on Inside Business Today, hosted by Bill Rancic and Giuliana Rancic. The segment, titled “Pioneering Life Sciences with High-Quality Bioreagents,” explored how Sino Biological is advancing biomedical research and drug discovery worldwide. The feature aired on Fox Business Network.
During the in-studio interview, Dr. Rob Burgess, Chief Business Officer, discussed how Sino Biological’s ‘commitment to consistency, reliability, and scientific excellence positioned the company as a trusted partner for researchers across academia, biotechnology, and pharmaceutical development,’ according to the company.
Founded in 2007 by Dr. Liangzhi Xie—whose vision was influenced by his work with the late Dr. Daniel Wang at MIT—Sino Biological was created to solve a critical problem in life sciences research: inconsistent and low-quality reagents that hinder progress and compromise results. From its inception, the company set out to become a dependable, end-to-end resource for researchers tackling the world’s most complex biological challenges.
Today, Sino Biological offers a catalog of more than 8,000 recombinant proteins and 14,000 antibodies, including its industry-leading ProVir viral antigen bank, supporting research in infectious diseases, oncology, immunology, neuroscience, and beyond. The company’s proprietary HPLC-based quality verification and ISO-certified facilities ensure lot-to-lot consistency—earning trust from scientists in more than 90 countries.
A key focus of the segment is Sino Biological’s ProPure line of ultra-pure, endotoxin-free recombinant proteins, produced at its state-of-the-art Houston Center for Bioprocessing. Designed specifically to support cell and gene therapy research, ProPure products meet the rigorous demands of translational science and advanced therapeutic development.
Viewers will also learn how Sino Biological’s acquisition of SignalChem Biotech in Canada expanded its offerings to include high-quality active enzymes—further strengthening its position as a one-stop shop for life sciences research.
Dr. Burgess brings more than 30 years of biotechnology leadership, including senior roles at Lexicon Pharmaceuticals and Stem Cell Sciences, helping guide Sino Biological’s mission to deliver reliable, scalable solutions for global research teams. Under his leadership, the company continues to invest in innovative platforms such as cell-free expression systems and SwiftStain pH-sensitive antibody dyes—tools designed to accelerate discovery and improve experimental precision.
“Sino Biological plays a vital role in advancing global health by giving scientists the tools they need to innovate with confidence,” said Bill and Giuliana Rancic. “Their dedication to quality and reliability truly sets them apart in the life sciences industry.”
“We’re proud to feature Sino Biological on Inside Business Today,” said Gila Stern, Vice President of Production. “Their work behind the scenes is instrumental to breakthroughs in medicine, diagnostics, and vaccine development worldwide.”
Viewers can tune in to Inside Business Today on Fox Business Network on February 1, 2026, at 4:30 PM EST to learn more about how Sino Biological is shaping the future of life sciences research.
For more information, visit www.sinobiological.com.
